LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/16/2025
Back to search
Official data from USPTO
HANALL BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
HANALL BIOPHARMA
ST13
US500000079389998Class
5, 35, 42
Filing
79389998
Registration
7617145
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
04/03/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 35, 42
Filing date
12/07/2023
Registration date
12/24/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
JOHNSON, AISHA CLARKE
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Hanall Biopharma Co., Ltd.
Representatives
John M. Kim IPLA, LLP
Technical classification
Nice Classes
Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical agents affecting sensory organs; thyroid and para-thyroid hormone preparations; tonicsmedicines for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; parasiticides; antiemetics; bronchodilating preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; veterinary preparations for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; prescription synthetic narcotics; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for immunity improvement; pharmaceutical agents for treating physically caused lesions; pharmaceuticals for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of urogenital organs; vitamin preparations; pharmaceutical products for the treatment of bone diseases; preparations of trace elements for human and animal use for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; nervines in the nature of herbal supplements; pharmaceutical preparations for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; chemico-pharmaceutical preparations for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; medicines for the treatment of gastrointestinal diseases; drugs for medical purposes for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; medical diagnostic reagents; diuretics; medicines for human purposes for the treatment of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; antacids; haematogen; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis of autoimmune diseaseocular diseaseear diseaseneurodegenerative diseasecancer; sedatives; analgesics; medical preparations for slimming purposes; dental impression material for dental and dental technical purposes; medicines for dental purposes; dermatological pharmaceutical products; antibiotic preparations; antibiotics; anti-cancer preparations; blood solvents for medical or veterinary purposes; pharmaceutical preparations for the treatment of respiratory organs; preparations for the treatment of burns; chemotherapeutics; medications to treat chemical disorders
Class 35
Price comparison services; advertising services; distribution of samples; wholesale store services featuring nutraceuticals for use as a dietary supplement; wholesale store services featuring medical apparatus; wholesale store services featuring medical apparatus and instruments; advertising agency services for pharmaceuticals; wholesale store services featuring pharmaceuticals; wholesale store services featuring medicines for human purposes; wholesale store services featuring nutraceuticals via the internet; wholesale store services featuring make-up preparations
Class 42
Advice in the field of construction drafting; engineering surveying; rental of scientific equipment; research relating to mechanical engineering; meteorological observation for others; services for assessing the safety of agricultural chemicals; cosmetology research; industrial design; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; scientific research in the fields of medicinehealth and pharmacology; medical research; product safety testing; textile design; research in the field of computer software development; marineaerial and land surveying; oceanography research; chemical analysis; scientific research in the nature of providing environmental monitoring services
Publications
History of USPTO decisions and trademark events.
19 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/22/2024
PUBO
PUBLISHED FOR OPPOSITION
10/22/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/06/2024
RFNT
REFUSAL PROCESSED BY IB
08/04/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/17/2024
RFRR
REFUSAL PROCESSED BY MPU
07/17/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/26/2024
CNRT
NON-FINAL ACTION WRITTEN
06/25/2024
DOCK
ASSIGNED TO EXAMINER
06/21/2024
MAFR
APPLICATION FILING RECEIPT MAILED
02/27/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/23/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/22/2024
Continuous trademark protection
Get notified about every new filing that threatens HANALL BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.